by bmi_wpadmin | Dec 10, 2024 | BayMedica, Cannabinoids
Unlocking Innovation in Cannabinoids In the cannabis industry, unlocking the potential of rare cannabinoids is crucial to advancing innovation and meeting the rising demand for precision health and wellness products. Nature has gifted us with a remarkable...
by bmi_wpadmin | Sep 23, 2024 | BayMedica, Research
The cannabis industry has moved one step closer to discovering the perfect, non-intoxicating therapeutic solution for bodily discomfort. Recent findings from a groundbreaking study on the effects of CBD and minor cannabinoids on pain, conducted by Radicle Science in...
by bmi_wpadmin | Sep 23, 2024 | BayMedica, Cannabidivarin (CBDV), Cannabinoids
Cannabidivarin, also known as CBDV, is a rare non-intoxicating cannabinoid first isolated in 1969. CBDV may share a similar name to its well-known cousin, cannabidiol, or CBD, but unlike CBD, CBDV is a minor cannabinoid and has demonstrated unique physiological...
by bmi_wpadmin | Sep 23, 2024 | BayMedica, Partners, Product Actualization
A Guide for CPG Brands Leveraging Minor Cannabinoids As the demand for cannabinoid-infused beverages continues to surge, CPG brands and product developers have a unique opportunity to enter this growing market with innovative, compliant, and consumer-focused products....
by bmi_wpadmin | Sep 15, 2022 | BayMedica
If you have been in the cannabis/cannabinoid industry for any amount of time, you may have encountered the term “entourage effect.” So what exactly is the entourage effect? For starters, it has nothing to do with the—somewhat questionable—2000s TV series. Instead, it...
Recent Comments